190 related articles for article (PubMed ID: 16892042)
1. CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding.
Adam PJ; Terrett JA; Steers G; Stockwin L; Loader JA; Fletcher GC; Lu LS; Leach BI; Mason S; Stamps AC; Boyd RS; Pezzella F; Gatter KC; Harris AL
Br J Cancer; 2006 Aug; 95(3):298-306. PubMed ID: 16892042
[TBL] [Abstract][Full Text] [Related]
2. Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates.
Law CL; Gordon KA; Toki BE; Yamane AK; Hering MA; Cerveny CG; Petroziello JM; Ryan MC; Smith L; Simon R; Sauter G; Oflazoglu E; Doronina SO; Meyer DL; Francisco JA; Carter P; Senter PD; Copland JA; Wood CG; Wahl AF
Cancer Res; 2006 Feb; 66(4):2328-37. PubMed ID: 16489038
[TBL] [Abstract][Full Text] [Related]
3. pVHL/HIF-regulated CD70 expression is associated with infiltration of CD27+ lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma.
Ruf M; Mittmann C; Nowicka AM; Hartmann A; Hermanns T; Poyet C; van den Broek M; Sulser T; Moch H; Schraml P
Clin Cancer Res; 2015 Feb; 21(4):889-98. PubMed ID: 25691774
[TBL] [Abstract][Full Text] [Related]
4. Immune escape for renal cell carcinoma: CD70 mediates apoptosis in lymphocytes.
Diegmann J; Junker K; Loncarevic IF; Michel S; Schimmel B; von Eggeling F
Neoplasia; 2006 Nov; 8(11):933-8. PubMed ID: 17132225
[TBL] [Abstract][Full Text] [Related]
5. A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma.
Pal SK; Forero-Torres A; Thompson JA; Morris JC; Chhabra S; Hoimes CJ; Vogelzang NJ; Boyd T; Bergerot PG; Adashek JJ; Li H; Yu X; Gartner EM; Carret AS; Smith DC
Cancer; 2019 Apr; 125(7):1124-1132. PubMed ID: 30624766
[TBL] [Abstract][Full Text] [Related]
6. Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma.
Wang QJ; Hanada K; Robbins PF; Li YF; Yang JC
Cancer Res; 2012 Dec; 72(23):6119-29. PubMed ID: 23071066
[TBL] [Abstract][Full Text] [Related]
7. Plasma CD27, a Surrogate of the Intratumoral CD27-CD70 Interaction, Correlates with Immunotherapy Resistance in Renal Cell Carcinoma.
Benhamouda N; Sam I; Epaillard N; Gey A; Phan L; Pham HP; Gruel N; Saldmann A; Pineau J; Hasan M; Quiniou V; Nevoret C; Verkarre V; Libri V; Mella S; Granier C; Broudin C; Ravel P; De Guillebon E; Mauge L; Helley D; Jabla B; Chaput N; Albiges L; Katsahian S; Adam J; Mejean A; Adotevi O; Vano YA; Oudard S; Tartour E
Clin Cancer Res; 2022 Nov; 28(22):4983-4994. PubMed ID: 36067339
[TBL] [Abstract][Full Text] [Related]
8. Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway.
Ji F; Zhang F; Zhang M; Long K; Xia M; Lu F; Li E; Chen J; Li J; Chen Z; Jing L; Jia S; Yang R; Hu Z; Guo Z
J Hematol Oncol; 2021 Sep; 14(1):152. PubMed ID: 34556152
[TBL] [Abstract][Full Text] [Related]
9. CD70 is Consistently Expressed in Primary and Metastatic Clear Cell Renal Cell Carcinoma.
Huang RR; Chen Z; Kroeger N; Pantuck A; Said J; Kluger HM; Shuch B; Ye H
Clin Genitourin Cancer; 2024 Apr; 22(2):347-353. PubMed ID: 38195301
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma.
Panowski SH; Srinivasan S; Tan N; Tacheva-Grigorova SK; Smith B; Mak YSL; Ning H; Villanueva J; Wijewarnasuriya D; Lang S; Melton Z; Ghosh A; Dusseaux M; Galetto R; Heyen JR; Sai T; Van Blarcom T; Chaparro-Riggers J; Sasu BJ
Cancer Res; 2022 Jul; 82(14):2610-2624. PubMed ID: 35294525
[TBL] [Abstract][Full Text] [Related]
11. The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment.
Xiong Q; Wang H; Shen Q; Wang Y; Yuan X; Lin G; Jiang P
J Transl Med; 2024 Apr; 22(1):368. PubMed ID: 38637886
[TBL] [Abstract][Full Text] [Related]
12. CD70: a new tumor specific biomarker for renal cell carcinoma.
Junker K; Hindermann W; von Eggeling F; Diegmann J; Haessler K; Schubert J
J Urol; 2005 Jun; 173(6):2150-3. PubMed ID: 15879877
[TBL] [Abstract][Full Text] [Related]
13. CD70 antibody-drug conjugate as a potential therapeutic agent for uterine leiomyosarcoma.
Nakae R; Matsuzaki S; Serada S; Matsuo K; Shiomi M; Sato K; Nagase Y; Matsuzaki S; Nakagawa S; Hiramatsu K; Okazawa A; Kimura T; Egawa-Takata T; Kobayashi E; Ueda Y; Yoshino K; Naka T; Kimura T
Am J Obstet Gynecol; 2021 Feb; 224(2):197.e1-197.e23. PubMed ID: 32822640
[TBL] [Abstract][Full Text] [Related]
14. CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies.
Al Sayed MF; Ruckstuhl CA; Hilmenyuk T; Claus C; Bourquin JP; Bornhauser BC; Radpour R; Riether C; Ochsenbein AF
Blood; 2017 Jul; 130(3):297-309. PubMed ID: 28495792
[TBL] [Abstract][Full Text] [Related]
15. CD70 expression patterns in renal cell carcinoma.
Jilaveanu LB; Sznol J; Aziz SA; Duchen D; Kluger HM; Camp RL
Hum Pathol; 2012 Sep; 43(9):1394-9. PubMed ID: 22401771
[TBL] [Abstract][Full Text] [Related]
16. Anti-CD70 immunocytokines for exploitation of interferon-γ-induced RIP1-dependent necrosis in renal cell carcinoma.
Chen P; Nogusa S; Thapa RJ; Shaller C; Simmons H; Peri S; Adams GP; Balachandran S
PLoS One; 2013; 8(4):e61446. PubMed ID: 23613854
[TBL] [Abstract][Full Text] [Related]
17. CD70 is downregulated by interaction with CD27.
Kuka M; Munitic I; Giardino Torchia ML; Ashwell JD
J Immunol; 2013 Sep; 191(5):2282-9. PubMed ID: 23913967
[TBL] [Abstract][Full Text] [Related]
18. Structural delineation and phase-dependent activation of the costimulatory CD27:CD70 complex.
Liu W; Maben Z; Wang C; Lindquist KC; Li M; Rayannavar V; Lopez Armenta I; Nager A; Pascua E; Dominik PK; Oyen D; Wang H; Roach RC; Allan CM; Mosyak L; Chaparro-Riggers J
J Biol Chem; 2021 Oct; 297(4):101102. PubMed ID: 34419446
[TBL] [Abstract][Full Text] [Related]
19. Reciprocal expression of CD70 and of its receptor, CD27, in human long term-activated T and natural killer (NK) cells: inverse regulation by cytokines and role in induction of cytotoxicity.
Orengo AM; Cantoni C; Neglia F; Biassoni R; Ferrini S
Clin Exp Immunol; 1997 Mar; 107(3):608-13. PubMed ID: 9067541
[TBL] [Abstract][Full Text] [Related]
20. CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma.
Park YP; Jin L; Bennett KB; Wang D; Fredenburg KM; Tseng JE; Chang LJ; Huang J; Chan EKL
Oral Oncol; 2018 Mar; 78():145-150. PubMed ID: 29496042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
